Listed

EDGEWELL PERSONAL CARE Co: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 4, 2022 and accepted by EDGAR at Aug 4, 2022, 11:11 ET.

Share

Management's discussion and analysis

As filed, 40,788 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(Amounts in millions, except per share data, unaudited)

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the accompanying notes included in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K filed with the SEC on November 19, 2021 (the “2021 Annual Report”). The following discussion may contain forward-looking statements that reflect our plans, estimates, and beliefs and involve risks, uncertainties, and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed within “Forward-Looking Statements” below and in Item 1A. Risk Factors and “Forward-Looking Statements” included within our 2021 Annual Report.

Forward-Looking Statements

This document contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of Edgewell Personal Care Company (“Edgewell,” “we” or “our Company”) or any of our businesses. Forward-looking statements generally can be identified by the use of words or phrases such as “believe,” “expect,” “expectation,” “anticipate,” “may,” “could,” “intend,” “belief,” “estimate,” “plan,” “target,” “predict,” “likely,” “will,” “should,” “forecast,” “outlook,” or other similar words or phrases. These statements are not based on historical facts, but instead reflect our expectations, estimates, or projections concerning future results or events, including, without limitation, the future earnings and performance of our Company or any of our businesses, and the integration of the Billie, Inc. (“Billie”) acquisition and expected benefits from this transaction, including growth opportunities and cost savings. Many factors outside our control could affect the realization of these estimates. These statements are not guarantees of performance and are inherently subject to known and unknown risks, uncertainties and assumptions that are difficult to predict and could cause our actual results to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or projections will be achieved. The forward-looking statements included in this report are only made as of the date of this report and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. You should not place undue reliance on these statements.

In addition, other risks and uncertainties not presently known to us or that we presently consider immaterial could significantly affect the forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Risks and uncertainties include those detailed from time to time in our publicly filed documents, including in Item 1A. Risk Factors of Part I of our 2021 Annual Report.

Non-GAAP Financial Measures

While we report financial results in accordance with GAAP, this discussion also includes non-GAAP measures. These non-GAAP measures are referred to as “adjusted” or “organic” and exclude items such as restructuring costs, acquisition and integration costs, and other non-standard items. Reconciliations of non-GAAP measures are included within this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. We use this non-GAAP information internally to make operating decisions and believe it is helpful to investors because it allows more meaningful period-to-period comparisons of ongoing operating results. Given certain significant events, including the acquisition of Billie, we view the use of non-GAAP measures that take into account the impact of these unique events as particularly valuable in understanding our underlying operational results and providing insights into future performance. The information can also be used to perform trend analysis and to better identify operating trends that may otherwise be masked or distorted by the types of items that are excluded. This non-GAAP information is also a component in determining management’s incentive compensation. Finally, we believe this information provides more transparency.

The following provides additional detail on our non-GAAP measures:

  • We analyze net sales and segment profit on an organic basis to better measure the comparability of results between periods. Organic net sales and organic segment profit exclude the impact of changes in foreign currency and the impact of the Billie acquisition.
  • Organic net sales will be unfavorably impacted in fiscal 2022 by the Billie acquisition as sales that were previously reported as third party sales to Billie are now included as inter-company sales.
  • Segment profit will be unfavorably impacted in fiscal 2022 as a result of a change in the timing of profit recognition due to the Billie acquisition. Subsequent to the acquisition of Billie, profit previously earned on sales to Billie will be deferred until Billie sells to a third party.
  • Additionally, we utilize “adjusted” non-GAAP measures including gross profit, SG&A, operating income, income taxes, net earnings, and diluted earnings per share internally to make operating decisions. The following items are excluded when analyzing non-GAAP measures: restructuring and related costs, acquisition and integration costs, stock keeping unit (“SKU”) rationalization charges, legal settlements and other non-standard items.

All comparisons are with the same period in the prior year, unless otherwise noted.

Industry and Market Data

Unless we indicate otherwise, we base the information contained or incorporated by reference herein, concerning our industry on our general knowledge and expectations. Our market position, market share, and industry market size are estimates based on internal and external data from various industry analyses, our internal research and adjustments, and assumptions that we believe to be reasonable. We have not independently verified data from industry analyses and cannot guarantee its accuracy or completeness. In addition, we believe that industry, market size, market position and market share data within our industry provides general guidance but is inherently imprecise and has not been verified by any independent source. Further, our estimates and assumptions involve risks and uncertainties and are subject to change based on various factors, including those discussed in Item 1A. Risk Factors in Part I of our 2021 Annual Report. These and other factors could cause results to differ materially from those expressed in the estimates and assumptions. You are cautioned not to place undue reliance on this data.

Retail sales for purposes of market size, market position and market share information are based on retail sales in U.S. dollars.

Trademarks and Trade Names

We own or have rights to use trademarks and trade names that we use in conjunction with the operation of our business, which appear throughout this Quarterly Report on Form 10-Q. We may also refer to brand names, trademarks, service marks and trade names of other companies and organizations, which are the property of their respective owners.

Impact of the COVID-19 Pandemic

Throughout the novel coronavirus 2019 (“COVID-19”) pandemic, we have taken and continue to take significant measures to protect our employees and businesses, while remaining in compliance with local and national guidelines.

The Company’s top priority during this time continues to be ensuring the health and welfare of our employees and additional health and safety measures have been put in place at all of our manufacturing locations. To date, we have not experienced a material operational disruption across our manufacturing or distribution facilities.

The prolonged COVID-19 pandemic environment has resulted in increased supply chain challenges across labor management, product procurement and distribution. The continued duration and severity of the COVID-19 pandemic may cause further disruptions related to our key suppliers, increase procurement and distribution costs and impact our ability to hire and retain employees, which may result in higher labor costs going forward. However, the impact, timing and severity of potential disruptions cannot be reasonably estimated at this time.

We expect to maintain adequate liquidity, and we will continue to assess the impact that the COVID-19 pandemic has on our liquidity needs and current economic market conditions. As noted within “Liquidity and Capital Resources” below, the COVID-19 pandemic has not had a significant impact on our liquidity, cash flows or capital resources.

Significant Events

Acquisitions

On November 29, 2021, the Company completed the acquisition of Billie, a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women, for a purchase price of $309.4, net of cash acquired. We purchased Billie utilizing a combination of cash on hand and drawing on our U.S. revolving credit facility due 2025 (“Revolving Credit Facility”). As a result, Billie became a wholly owned subsidiary of the Company. Refer to Note 2 of Notes to Condensed Consolidated Financial Statements for further discussion.

Executive Summary

The following is a summary of key results for the third quarter and first nine months of fiscal 2022 compared to the prior year period. Net earnings and earnings per share (“EPS”) for the periods presented were impacted by restructuring and related costs, acquisition and integration costs, and other non-standard items, as described in the table below. The impact of these items on reported net earnings and EPS are provided as a reconciliation of net earnings and EPS to adjusted net earnings and adjusted diluted EPS, both of which are non-GAAP measures.

Third Quarter of Fiscal 2022

  • Net sales in the third quarter of fiscal 2022 increased 8.7% to $623.8. Organic net sales increased 9.0% compared to the prior year quarter, with growth across all segments including strong growth in Sun Care, Feminine Care and Women’s shave across both North American and International markets.
  • Net earnings in the third quarter of fiscal 2022 were $30.5 compared to $40.8 in the prior year quarter. On an adjusted basis, net earnings for the third quarter of fiscal 2022 were $45.8 compared to $49.2 in the prior year quarter. Adjusted earnings declined compared to the prior year quarter despite higher net sales, due to lower gross margins from inflationary pressures including higher materials, labor, and warehousing and distribution costs.
  • Net earnings per diluted share during the third quarter of fiscal 2022 were $0.57 compared to $0.74 in the prior year quarter. On an adjusted basis, net earnings per diluted share during the third quarter of fiscal 2022 were $0.86 compared to $0.89 in the prior year quarter.
Three Months Ended June 30, 2022 Gross Profit SG&A Operating Income EBIT(1) Income taxes Net Earnings Diluted EPS
GAAP — Reported $240.6 $92.7 $49.9 $36.3 $5.8 $30.5 $0.57
Restructuring and related costs — 0.4 3.9 3.9 0.9 3.0 0.06
Acquisition and integration costs — 0.9 0.9 0.9 0.3 0.6 0.01
SKU rationalization charges 22.5 — 22.5 22.5 5.5 17.0 0.32
Legal settlement — (7.5) (7.5) (7.5) (1.8) (5.7) (0.11)
Sun Care reformulation costs — — 0.6 0.6 0.2 0.4 0.01
Total Adjusted Non-GAAP $263.1 $98.9 $70.3 $56.7 $10.9 $45.8 $0.86
GAAP as a percent of net sales 38.6% 14.9% 8.0% GAAP effective tax rate 16.1%
Adjusted as a percent of net sales 42.2% 15.9% 11.3% Adjusted effective tax rate 19.3%
Three Months Ended June 30, 2021 Gross Profit SG&A Operating Income EBIT(1) Income taxes Net Earnings Diluted EPS
GAAP — Reported $270.3 $97.5 $71.1 $53.9 $13.1 $40.8 $0.74
Restructuring and related costs 0.2 2.8 8.2 8.2 2.0 6.2 0.11
Acquisition and integration costs — 1.3 1.3 1.3 0.3 1.0 0.02
UK tax rate increase — — — — (1.2) 1.2 0.02
Total Adjusted Non-GAAP $270.5 $93.4 $80.6 $63.4 $14.2 $49.2 $0.89
GAAP as a percent of net sales 47.1% 17.0% 12.4% GAAP effective tax rate 24.2%
Adjusted as a percent of net sales 47.2% 16.3% 14.0% Adjusted effective tax rate 22.4%

(1) EBIT is defined as Earnings before Income taxes.

First Nine Months of Fiscal 2022

  • Net sales for the first nine months of fiscal 2022 increased 5.9% to $1,634.8. Organic net sales increased 4.8% compared to the prior year period, due to growth in Sun Care globally, growth in Wet Shave in International markets and growth in Women’s shave, Feminine Care and Grooming in North America.
  • Net earnings for the first nine months of fiscal 2022 were $64.9 compared to $72.9 in the prior year. On an adjusted basis, net earnings for the first nine months of fiscal 2022 were $96.0 compared to $111.0 in the prior year period. Adjusted earnings were down due to higher cost of goods sold from inflationary pressures, higher A&P and increased Selling, General and Administrative (“SG&A”) expense, largely related to amortization costs associated with the Billie acquisition.
  • Net earnings per diluted share during the first nine months of fiscal 2022 were $1.20 compared to $1.32 in the prior year period. On an adjusted basis, as illustrated in the following table, net earnings per diluted share during the first nine months of fiscal 2022 were $1.77 compared to $2.01 in the prior year quarter.
Nine Months Ended June 30, 2022 Gross Profit SG&A Operating Income EBIT(1) Income taxes Net Earnings Diluted EPS
GAAP — Reported $660.6 $290.9 $123.4 $79.6 $14.7 $64.9 $1.20
Restructuring and related costs — 0.6 9.8 9.8 2.5 7.3 0.14
Acquisition and integration costs 0.8 7.2 8.0 8.0 0.8 7.2 0.13
SKU rationalization charges 22.5 — 22.5 22.5 5.5 17.0 0.31
Legal settlement — (7.5) (7.5) (7.5) (1.8) (5.7) (0.11)
Value-added tax settlement costs — 3.4 3.4 3.4 1.1 2.3 0.04
Sun Care reformulation costs 3.5 — 4.1 4.1 1.1 3.0 0.06
Total Adjusted Non-GAAP $687.4 $287.2 $163.7 $119.9 $23.9 $96.0 $1.77
GAAP as a percent of net sales 40.4% 17.8% 7.5% GAAP effective tax rate 18.5%
Adjusted as a percent of net sales 42.0% 17.6% 10.0% Adjusted effective tax rate 20.0%
Nine Months Ended June 30, 2021 Gross Profit SG&A Operating Income EBIT(1) Income taxes Net Earnings Diluted EPS
GAAP — Reported $705.3 $284.0 $175.6 $98.6 $25.7 $72.9 $1.32
Restructuring and related costs 0.3 6.2 18.1 18.1 4.4 13.7 0.25
Acquisition and integration costs 1.3 3.3 4.6 4.6 1.1 3.5 0.06
Cost of early retirement of long-term debt — — — 26.1 6.4 19.7 0.36
UK tax rate increase — — — — (1.2) 1.2 0.02
Total Adjusted Non-GAAP $706.9 $274.5 $198.3 $147.4 $36.4 $111.0 $2.01
GAAP as a percent of net sales 45.7% 18.4% 11.4% GAAP effective tax rate 26.1%
Adjusted as a percent of net sales 45.8% 17.8% 12.8% Adjusted effective tax rate 24.8%

(1) EBIT is defined as Earnings before Income taxes.

Operating Results

The following table presents changes in net sales for the third quarter and first nine months of fiscal 2022, as compared to the corresponding period in fiscal 2021, and provides a reconciliation of organic net sales to reported amounts.

Net Sales

Net Sales - Total Company Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Net sales - fiscal 2021 $573.7 $1,544.1
Organic 51.4 9.0% 73.8 4.8%
Impact of Billie acquisition, net 21.1 3.7% 55.3 3.6%
Impact of currency (22.4) (4.0)% (38.4) (2.5)%
Net sales - fiscal 2022 $623.8 8.7% $1,634.8 5.9%

For the third quarter of fiscal 2022, net sales were $623.8, an increase of 8.7%, including a $21.1 or 3.7% impact from the acquisition of Billie and a $22.4 or 4.0% unfavorable impact from currency movements. Organic net sales increased 9.0%, reflecting increased volumes and higher pricing in the quarter. North America organic net sales increased 9.3% and International organic net sales increased 8.4%.

For the first nine months of fiscal 2022, net sales were $1,634.8, an increase of 5.9%, including a $55.3 or 3.6% impact from the acquisition of Billie and a $38.4 or 2.5% unfavorable impact from currency movements. Organic net sales increased 4.8% driven by increases across multiple product lines including Wet Shave, Sun Care, Grooming and Feminine Care. The increases were offset by declines in volumes in Skin Care.

For further discussion regarding net sales, including a summary of reported versus organic changes, see “Segment Results.”

Gross Profit

Gross profit was $240.6 during the third quarter of fiscal 2022, compared to $270.3 in the prior year quarter. Gross margin as a percent of net sales for the third quarter of fiscal 2022 was 38.6%. Included in Cost of products sold was a $22.5 charge for the write-off of inventory for certain Wet Ones SKUs and a related contract termination charge. Adjusted gross margin percentage was 42.2% compared to 47.2% in the prior year quarter, a decline of 500-basis points compared to the prior year quarter, as a 440-basis point net impact from higher commodity and transportation related costs net of productivity savings, and a 190-basis point combined impact from negative mix, higher trade spend and unfavorable currency, were only partly offset by the benefit from pricing.

Gross profit was $660.6 during the first nine months of fiscal 2022, compared to $705.3 in the prior year period. Gross margin as a percent of net sales for the first nine months of fiscal 2022 was 40.4% compared to 45.7% in the prior year period. Included in Cost of products sold was a $22.5 charge for the write-off of inventory for certain Wet Ones SKUs and a related contract termination charge. Adjusted gross margin percentage was 42.0%, down 380-basis points from 45.8% in the prior year period, driven by commodity inflation, higher warehousing and distribution expenses, and unfavorable product mix, which were partially offset by favorable pricing.

Selling, General and Administrative Expense

SG&A was $92.7 in the third quarter of fiscal 2022, or 14.9% of net sales, compared to $97.5 in the prior year quarter, or 17.0% of net sales. Included in SG&A was a $7.5 gain related to a favorable legal settlement. Adjusted SG&A as a percent of net sales was 15.9%, a decline of 40-basis points, as leverage from increased net sales, benefits from operational efficiency programs, and favorable currency translation more than offset the impact of the Billie acquisition, including amortization, and higher overall compensation expense.

SG&A was $290.9 in the first nine months of fiscal 2022, or 17.8% of net sales, compared to $284.0 in the prior year period, or 18.4% of net sales. Included in SG&A was a $7.5 gain related to a favorable legal settlement. Adjusted SG&A as a percent of net sales was 17.6%, a decline of 20-basis points, driven largely by leverage related to higher total net sales and the benefit from operational efficiency programs. The decline was partially offset by additional costs incurred associated with the Billie acquisition, including amortization expense as well as overall inflation.

Advertising and Sales Promotion Expense

For the third quarter of fiscal 2022, A&P was $80.9, down $1.0 compared to the prior year quarter of $81.9. A&P as a percent of net sales was 13.0%, as compared to 14.3% in the prior year quarter as increased spending in support of Billie, Feminine Care and sun season execution were more than offset by lower spend in International markets, and the impact of currency translation.

For the first nine months of fiscal 2022, A&P was $197.0, up $5.5 compared to the prior year period. A&P as a percent of net sales was 12.1%, down from 12.4% in the prior year period. The increase in A&P expense was primarily driven by increases in support of Sun Care after the COVID-19 pandemic-related declines in the prior year and additional A&P expense for Grooming products.

Research and Development Expense

Research and development expense (“R&D”) for the third quarter of fiscal 2022 was $13.6, compared to $14.6 in the prior year quarter. As a percent of net sales, R&D was 2.2% in the third quarter of fiscal 2022 compared to 2.5% in the prior year quarter. R&D for the first nine months of fiscal 2022 was $40.1, compared to $42.6 in the prior year period. As a percent of net sales, R&D was 2.5% in the first nine months of fiscal 2022, compared to 2.8% in the prior year period. R&D expense was down compared to the prior year driven primarily by lower program spend.

Interest Expense Associated with Debt

Interest expense associated with debt for the third quarter of fiscal 2022 was $18.0, compared to $16.4 in the prior year quarter. For the first nine months of fiscal 2022, interest expense was $53.3 compared to $51.1 in the prior year period. The increase in interest expense was the result of higher overall debt balance from draws on the Revolving Credit Facility in fiscal 2022 primarily to finance the acquisition of Billie.

Other (Income) Expense, net

Other (income) expense, net was income of $4.4 in the third quarter of fiscal 2022, compared to expense of $0.8 in the prior year quarter. Other (income) expense, net was income of $9.5 during the first nine months of fiscal 2022, compared to income of $0.2 during the first nine months of fiscal 2021. The increase in income was driven by favorable foreign currency hedge settlements compared to the prior year, which helped to offset other negative operational impacts from currency.

Income Tax Provision

The effective tax rate for the three and nine months ended June 30, 2022 was 16.1% and 18.5%, respectively, compared to 24.2% and 26.1% in the prior year period, respectively. On an adjusted basis, the effective tax rate was 19.3% and 20.0% for the three and nine months ended June 30, 2022, respectively, and 22.4% and 24.8% for the three and nine months ended June 30, 2021, respectively. The fiscal 2022 effective tax rate and adjusted effective tax rate reflect a favorable mix of earnings in low tax jurisdictions and a favorable impact of a change in our prior estimates.

Operating Model Redesign

In fiscal 2022, we are taking specific actions to strengthen our operating model, simplify our organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, we expect to incur one-time charges of approximately $15 in fiscal 2022. We incurred $3.9 and $9.8 during the third quarter and first nine months of fiscal 2022, respectively, primarily related to employee severance and benefit costs.

Segment Results

The following tables present changes in segment net sales and segment profit for the third quarter and first nine months of fiscal 2022, compared to the corresponding periods in fiscal 2021, and provide a reconciliation of organic segment net sales and organic segment profit to reported amounts. For a reconciliation of segment profit to Earnings before income taxes, refer to Note 15 of Notes to Condensed Consolidated Financial Statements.

Our operating model includes some shared business functions across segments, including product warehousing and distribution, transaction processing functions and, in most cases, a combined sales force and management teams. We apply a fully allocated cost basis in which shared business functions are allocated between segments.

Net sales and segment profit activity related to Billie products were included in the Wet Shave segment for the post-acquisition period.

Wet Shave

Net Sales - Wet Shave Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Net sales - fiscal 2021 $304.9 $876.7
Organic 19.1 6.3% 19.0 2.2%
Impact of Billie acquisition, net 21.1 6.9% 55.3 6.3%
Impact of currency (18.8) (6.2)% (33.6) (3.9)%
Net sales - fiscal 2022 $326.3 7.0% $917.4 4.6%

Wet Shave net sales for the third quarter of fiscal 2022 increased 7.0% compared to the prior year quarter, inclusive of a 6.9% increase from the acquisition of Billie and a 6.2% decline due to currency movements. Organic net sales increased $19.1, or 6.3%, driven by increases in Men’s and Women’s Systems, Disposables, and Shave Preps. Organic net sales in North America increased 5.2%, reflecting higher volumes and price, while International organic net sales increased 7.1%, primarily driven by higher volumes.

Wet Shave net sales for the first nine months of fiscal 2022 increased 4.6%, inclusive of a 6.3% increase from the acquisition of Billie and a 3.9% decline due to currency movements. Organic net sales increased 2.2% compared to the prior year driven by increases in Women’s Systems, Disposables, and Shave Preps, offset by declines in Men’s Systems. Organic net sales in International markets increased 4.2% compared to declines in North America of 0.4%.

Segment Profit - Wet Shave Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Segment profit - fiscal 2021 $43.1 $141.6
Organic 0.2 0.5% (7.5) (5.3)%
Impact of Billie acquisition, net (1.0) (2.3)% (8.6) (6.1)%
Impact of currency (4.8) (11.2)% (8.9) (6.3)%
Segment profit - fiscal 2022 $37.5 (13.0)% $116.6 (17.7)%

Wet Shave segment profit for the third quarter of fiscal 2022 was $37.5, down $5.6, or 13.0%. Organic segment profit increased $0.2, or 0.5%, reflecting lower A&P expense, partially offset by lower gross profit.

Wet Shave segment profit for the first nine months of fiscal 2022 was $116.6, down $25.0, or 17.7%. Organic segment profit decreased $7.5, or 5.3%, primarily due to inflationary pressures resulting in higher commodity costs and warehousing and distribution costs, partially offset by favorable pricing and lower A&P expense.

Sun and Skin Care

Net Sales - Sun and Skin Care Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Net sales - fiscal 2021 $195.2 $457.7
Organic 24.6 12.6% 51.4 11.2%
Impact of currency (3.6) (1.8)% (4.8) (1.0)%
Net sales - fiscal 2022 $216.2 10.8% $504.3 10.2%

Sun and Skin Care net sales for the third quarter of fiscal 2022 increased 10.8%. Organic net sales increased $24.6, or 12.6%. The increase in organic net sales was largely driven by Sun Care organic growth of approximately 15%, reflecting distribution gains in North America and continued category recovery in International markets. Additionally, Grooming organic net sales increased 7.5%, driven by 14% growth in International, while Wet Ones organic net sales returned to growth, increasing 7.4%.

Sun and Skin Care net sales for the first nine months of fiscal 2022 increased 10.2%. Organic net sales increased $51.4, or 11.2%. Organic net sales increases were driven by higher Sun Care volumes, resulting in growth of 23% globally, partially offset by unfavorable trade and coupons. Men’s Grooming increased 7%, driven by Cremo and Jack Black. Wet Ones organic net sales declined 23%, driven by lower volumes as demand fell during the first six months of fiscal 2022 to pre-COVID-19 pandemic levels.

Segment Profit - Sun and Skin Care Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Segment profit - fiscal 2021 $45.0 $86.4
Organic 2.2 4.9% 6.9 8.0%
Impact of currency (0.6) (1.3)% (0.7) (0.8)%
Segment profit -fiscal 2022 $46.6 3.6% $92.6 7.2%

Segment profit for the third quarter of fiscal 2022 was $46.6, an increase of $1.6. Organic segment profit increased $2.2, as higher sales in Sun Care were partially offset by inflationary cost pressures and higher A&P spend.

Segment profit for the first nine months of fiscal 2022 was $92.6, an increase of $6.2, or 7.2%. Organic segment profit increased $6.9, or 8.0%, driven primarily by higher sales volumes, partially offset by inflationary cost pressures and higher A&P expense.

Feminine Care

Net Sales - Feminine Care Period Ended June 30, 2022 Q3 % Chg Nine Months % Chg
Net sales - fiscal 2021 $73.6 $209.7
Organic 7.7 10.5% 3.4 1.6%
Impact of currency — —% — —%
Net sales - fiscal 2022 $81.3 10.5% $213.1 1.6%

Feminine Care net sales for the third quarter of fiscal 2022 increased $7.7, or 10.5%. The increase in net sales reflected higher category consumption and improved product availability and shelf replenishment.

Feminine Care net sales for the first nine months of fiscal 2022 increased $3.4, or 1.6%. The increase in net sales reflected higher category consumption compared to the prior year.

Segment Profit - Feminine Care Period Ended June 30, 2022 Q3 %Chg Nine Months %Chg
Segment profit -fiscal 2021 $13.7 $28.1
Organic (4.8) (35.1)% (9.0) (32.0)%
Impact of currency (0.1) (0.7)% — —%
Segment profit - fiscal 2022 $8.8 (35.8)% $19.1 (32.0)%

Feminine Care segment profit for the third quarter of fiscal 2022 was $8.8, a decrease of $4.9, or 35.8%, largely driven by lower gross profit, reflecting higher commodity and transportation related costs, as well as increased A&P support.

Feminine Care segment profit for the first nine months of fiscal 2022 was $19.1 a decrease of $9.0, or 32.0%, primarily due to inflationary pressures on materials and distribution, partially offset by favorable pricing.

General Corporate and Other Expenses

Quarter Ended June 30, 2022 2021 Nine Months Ended June 30, 2022 2021
Corporate expenses $14.8 $15.7 $42.8 $41.2
Restructuring and related costs 3.9 8.2 9.8 18.1
Acquisition and integration costs 0.9 1.3 8.0 4.6
SKU rationalization charges 22.5 — 22.5 —
Legal settlement (7.5) — (7.5) —
Value-added tax settlement costs — — 3.4 —
Sun Care reformulation costs 0.6 — 4.1 —
Cost of early retirement of long-term debt — — — 26.1
General corporate and other expenses $35.2 $25.2 $83.1 $90.0
% of net sales 5.6% 4.4% 5.1% 5.8%

For the third quarter of fiscal 2022, corporate expenses were $14.8, or 2.4% of net sales, compared to $15.7, or 2.7% of net sales. For the first nine months of fiscal 2022, corporate expenses were $42.8, or 2.6% of net sales, compared to $41.2, or 2.7% of net sales. For the third quarter of fiscal 2022, the decline in corporate expense was primarily due to lower discretionary spending. For the nine months ended June 30, 2022, the increase in corporate expense was primarily due to higher salary and benefit costs.

Liquidity and Capital Resources

At June 30, 2022, a portion of our cash balances were located outside the U.S. Given our extensive international operations, a significant portion of our cash is denominated in foreign currencies. Refer to Note 14 of Notes to Condensed Consolidated Financial Statements for a discussion of the primary currencies to which the Company is exposed. We manage our worldwide cash requirements by reviewing available funds among the many subsidiaries through which we conduct business and the cost effectiveness with which those funds can be accessed. We generally repatriate a portion of current year earnings from select non-U.S. subsidiaries only if the economic cost of the repatriation is not considered material.

The counterparties that hold our deposits consist of major financial institutions. We consistently monitor positions with, and the credit ratings of, counterparties both internally and by using outside ratings agencies.

Our total borrowings were $1,389.9 at June 30, 2022, including $139.9 tied to variable interest rates. Our total borrowings at September 30, 2021 were $1,276.5. We had outstanding borrowings of $121.0 under the Revolving Credit Facility at June 30, 2022, primarily to fund the acquisition of Billie. Taking into account outstanding letters of credit of $6.5, as of June 30, 2022, $297.5 was available under the Revolving Credit Facility. We had outstanding international borrowings, recorded in Notes payable, of $18.9 and $26.5 as of June 30, 2022 and September 30, 2021, respectively.

Effective February 7, 2022, we increased the maximum receivables sold facility amount under the Sixth Amendment to Master Accounts Receivable Purchase Agreement to $180.0 from $150.0. Refer to Note 9 of Notes to Condensed Consolidated Financial Statements for further discussion on our Accounts Receivable Facility.

Historically, we have generated, and expect to continue to generate, positive cash flows from operations. Our cash flows are affected by the seasonality of our Sun Care products, typically resulting in higher net sales and increased cash generated in the second and third quarter of each fiscal year. While we cannot reasonably estimate the full impact of the COVID-19 pandemic will have on our cash flows, we believe our cash on hand, cash flows from operations and borrowing capacity under our Revolving Credit Facility will be sufficient to satisfy our future working capital requirements, interest payments, R&D activities, capital expenditures, and other financing requirements for at least the next 12 months. We will continue to monitor our cash flows, spending and liquidity needs.

To date, the COVID-19 pandemic has not had a significant impact on our liquidity or capital resources. However, the COVID-19 pandemic has led to disruption and volatility in the global capital markets, which, depending on future developments, could impact our capital resources and liquidity in the future.

Short-term financing needs consist primarily of working capital requirements and principal and interest payments on our long-term debt. Long-term financing needs will depend largely on potential growth opportunities, including acquisition activity and repayment or refinancing of our long-term debt obligations. Our long-term liquidity may be influenced by our ability to borrow additional funds, renegotiate existing debt, and raise equity on terms that are favorable to us. We may, from time-to-time, seek to repurchase shares of our common stock. Such repurchases, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

As of June 30, 2022, we were in compliance with the provisions and covenants associated with our debt agreements.

Cash Flows

A summary of our cash flow activities is provided in the following table:

Net cash from (used by): Nine Months Ended June 30, 2022 2021
Operating activities $72.4 $155.9
Investing activities (337.6) (26.1)
Financing activities (21.4) (59.9)
Effect of exchange rate changes on cash (11.0) 2.9
Net (decrease) increase in cash and cash equivalents $(297.6) $72.8

Operating Activities

Cash flow from operating activities was $72.4 during the first nine months of fiscal 2022, compared to $155.9 during the prior year period. The decrease in cash flows versus the same period in the prior year was driven by a larger net working capital build.

Investing Activities

Cash flow used by investing activities was $337.6 during the first nine months of fiscal 2022, compared to $26.1 used during the prior year period. We completed the acquisition of Billie for $309.4, net of cash acquired, in fiscal 2022. Additionally, we collected $5.0 of proceeds from the sale of the Infant and Pet Care business during the first nine months of fiscal 2022, compared to $7.5 in the prior year period. Capital expenditures were $37.4 during the first nine months of fiscal 2022, compared to $34.1 in the prior year period.

Financing Activities

Net cash used by financing activities was $21.4 during the first nine months of fiscal 2022, compared to $59.9 in the prior year period. During the first nine months of fiscal 2022, we had net borrowings of $121.0 under our Revolving Credit Facility, primarily to fund the acquisition of Billie. We repurchased $110.1 of our common stock under our 2018 Board authorization to repurchase our common stock (the “Repurchase Plan”) compared to $9.2 in the prior year period. Dividend payments totaled $24.7 in the first nine months of fiscal 2022, compared to $16.7 in the prior year period. We had financing outflows for employee equity awards held for taxes totaling $10.4 in the first nine months of fiscal 2022, compared to $4.0 in the prior year period. In fiscal 2021, we replaced our $500 2022 Senior Notes with the issuance of $500 2029 Senior Notes. Additional financing cash outflows incurred in fiscal 2021 were related to costs of early debt retirement of the 2022 Senior Notes totaling $26.1 and debt issuance costs of $6.5.

Share Repurchases

During the first nine months of fiscal 2022, we repurchased 2.9 shares of our common stock for $110.1. We have 6.9 shares remaining under the Repurchase Plan. Future share repurchases, if any, would be made in the open market, privately negotiated transactions or otherwise, in such amounts and at such times as we deem appropriate based upon prevailing market conditions, business needs and other factors.

Dividends

On February 4, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter. The dividend was paid April 5, 2022, to stockholders of record as of the close of business on March 8, 2022.

On May 6, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the second fiscal quarter. The dividend was paid July 7, 2022, to stockholders of record as of the close of business on June 2, 2022.

Dividends declared during the nine months ended June 30, 2022 totaled $24.7. Payments made for dividends during the nine months ended June 30, 2022 totaled $24.7.

On July 29, 2022, the Board of Directors declared a quarterly cash dividend of $0.15 per common share for the third fiscal quarter. The dividend will be payable on October 5, 2022 to shareholders of record as of the close of business on September 2, 2022.

Commitments and Contingencies

Contractual Obligations

At June 30, 2022, we had outstanding borrowings of $121.0 under the Revolving Credit Facility. As of June 30, 2022, future minimum repayments of debt were: $121.0 in fiscal 2025, $750.0 in fiscal 2028 and $500.0 in fiscal 2029.

There have been no other material changes in our contractual obligations since the presentation in our 2021 Annual Report.

Critical Accounting Policies

Our critical accounting policies and estimates are fully described in our Annual Report on Form 10-K for the year ended September 30, 2021, as filed with the Securities and Exchange Commission ( the “SEC”) on November 19, 2021. The preparation of these financial statements requires us to make estimates and assumptions. These estimates and assumptions can be subjective and complex, and consequently, actual results could differ from those estimates. There have been no significant changes to our critical accounting policies and estimates since September 30, 2021.

Market risk

As filed, 1,253 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(Amounts in millions)

The market risk inherent in our financial instruments and positions represents the potential loss arising from adverse changes in currency rates, commodity prices, and interest rates. At times, we enter into contractual arrangements (derivatives) to reduce these exposures. For further information on our foreign currency derivative instruments, refer to Note 14 of Notes to Condensed Consolidated Financial Statements. As of June 30, 2022, there were no open derivative or hedging instruments for future purchases of raw materials or commodities. Our exposure to interest rate risk relates primarily to our variable-rate debt instruments, which currently bear interest based on LIBOR plus margin. As of June 30, 2022, our outstanding variable-rate debt included $139.9 related to our Revolving Credit Facility and international, variable-rate notes payable. Assuming a one-percent increase in the applicable interest rates, annual interest expense on these variable-rate debt instruments would increase approximately $1.4.

There have been no material changes in our assessment of market risk sensitivity since our presentation of Quantitative and Qualitative Disclosures About Market Risk in our 2021 Annual Report on Form 10-K.

Controls and procedures

As filed, 1,143 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2022. Based on that evaluation, our CEO and CFO concluded that, as of that date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have materially affected, or are likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-04-01 to 2022-06-30$623.8mus-gaap:Revenues
Revenue9 months2021-10-01 to 2022-06-30$1.63bnus-gaap:Revenues
Cost of revenue3 months2022-04-01 to 2022-06-30$383.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-10-01 to 2022-06-30$974.2mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2022-04-01 to 2022-06-30$240.6mus-gaap:GrossProfit
Gross profit9 months2021-10-01 to 2022-06-30$660.6mus-gaap:GrossProfit
Research and development3 months2022-04-01 to 2022-06-30$13.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-10-01 to 2022-06-30$40.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-04-01 to 2022-06-30$92.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-10-01 to 2022-06-30$290.9mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-04-01 to 2022-06-30$49.9mus-gaap:OperatingIncomeLoss
Operating income9 months2021-10-01 to 2022-06-30$123.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-04-01 to 2022-06-30$18.0mus-gaap:InterestExpense
Interest expense9 months2021-10-01 to 2022-06-30$53.3mus-gaap:InterestExpense
Income tax3 months2022-04-01 to 2022-06-30$5.8mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-10-01 to 2022-06-30$14.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-04-01 to 2022-06-30$30.5mus-gaap:NetIncomeLoss
Net income9 months2021-10-01 to 2022-06-30$64.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-04-01 to 2022-06-30$0.57us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-10-01 to 2022-06-30$1.20us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-04-01 to 2022-06-30$0.58us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-10-01 to 2022-06-30$1.21us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-04-01 to 2022-06-3053,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-10-01 to 2022-06-3054,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-10-01 to 2022-06-30$72.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-10-01 to 2022-06-30$37.4mus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid9 months2021-10-01 to 2022-06-30$24.7mus-gaap:PaymentsOfDividends
Share repurchases9 months2021-10-01 to 2022-06-30$110.1mus-gaap:PaymentsForRepurchaseOfCommonStock
Current assetsAt period end2022-06-30$933.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$3.72bnus-gaap:Assets
Current liabilitiesAt period end2022-06-30$575.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$2.24bnus-gaap:Liabilities
Long-term debtAt period end2022-06-30$1.36bnus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2022-06-30$1.48bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001096752-22-000027. Last ingested by Listed: Nov 14, 2026, 23:53 ET. Listed shows no prices and gives no investment advice.